News Quantified

TTNP – titan pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Form NT 10-Q TITAN PHARMACEUTICALS For: Sep 30

Form 8-K TITAN PHARMACEUTICALS For: Nov 06

Form 8-K TITAN PHARMACEUTICALS For: Oct 24

Top News Gainers

1/16 Form 8-K TITAN PHARMACEUTICALS For: Jan 16 32.0%

3/2 Form 8-K TITAN PHARMACEUTICALS For: Mar 02 23.8%

12/3 Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference 22.3%

9/18 Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant 20.9%

12/30 Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors 10.3%

6/4 Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine® 9.6%

3/5 Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants 9.5%

10/23 Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 8.7%

10/22 Form SC 13G TITAN PHARMACEUTICALS Filed by: Empery Asset Management, LP 8.5%

8/15 Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. 7.0%

Top News Decliners

10/16 Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering -41.9%

8/14 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.170 ActVsEst (0.210) - Miss -37.4%

11/14 Form 10-Q TITAN PHARMACEUTICALS For: Sep 30 -21.5%

8/7 Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering -20.7%

3/30 Form 10-K TITAN PHARMACEUTICALS For: Dec 31 -17.1%

1/7 Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering -16.3%

1/9 Form D TITAN PHARMACEUTICALS -12.1%

12/31 Form DEFA14A TITAN PHARMACEUTICALS -11.8%

2/12 Form DEFA14A TITAN PHARMACEUTICALS -9.4%

6/26 Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine -9.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day